User menu

Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Bibliographic reference Emery, Paul ; Fleischmann, Roy M ; Doyle, Mittie K ; Strusberg, Ingrid ; Durez, Patrick ; et. al. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.. In: Arthritis Care & Research, Vol. 65, no.11, p. 1732-1742 (2013)
Permanent URL http://hdl.handle.net/2078.1/156557
  1. Herman Sonja, Krönke Gerhard, Schett Georg, Molecular mechanisms of inflammatory bone damage: emerging targets for therapy, 10.1016/j.molmed.2008.04.001
  2. Maini Ravinder, St Clair E William, Breedveld Ferdinand, Furst Daniel, Kalden Joachim, Weisman Michael, Smolen Josef, Emery Paul, Harriman Gregory, Feldmann Marc, Lipsky Peter, Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, 10.1016/s0140-6736(99)05246-0
  3. Lipsky Peter E., van der Heijde Desiree M.F.M., St. Clair E. William, Furst Daniel E., Breedveld Ferdinand C., Kalden Joachim R., Smolen Josef S., Weisman Michael, Emery Paul, Feldmann Marc, Harriman Gregory R., Maini Ravinder N., Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis, 10.1056/nejm200011303432202
  4. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Furst D., Weisman M. H., St.Clair E. W., Keenan G. F., van der Heijde D., Marsters P. A., Lipsky P. E., , Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate, 10.1002/art.20159
  5. St. Clair E. William, van der Heijde D�sir�e M. F. M., Smolen Josef S., Maini Ravinder N., Bathon Joan M., Emery Paul, Keystone Edward, Schiff Michael, Kalden Joachim R., Wang Ben, DeWoody Kimberly, Weiss Roberta, Baker Daniel, , Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial, 10.1002/art.20568
  6. Weinblatt Michael E., Keystone Edward C., Furst Daniel E., Moreland Larry W., Weisman Michael H., Birbara Charles A., Teoh Leah A., Fischkoff Steven A., Chartash Elliot K., Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial, 10.1002/art.10697
  7. Furst, J Rheumatol, 30, 2563 (2003)
  8. Moreland Larry W., Etanercept Therapy in Rheumatoid Arthritis : A Randomized, Controlled Trial, 10.7326/0003-4819-130-6-199903160-00004
  9. Bathon Joan M., Martin Richard W., Fleischmann Roy M., Tesser John R., Schiff Michael H., Keystone Edward C., Genovese Mark C., Wasko Mary Chester, Moreland Larry W., Weaver Arthur L., Markenson Joseph, Finck Barbara K., A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis, 10.1056/nejm200011303432201
  10. Klareskog Lars, van der Heijde Désirée, de Jager Julien P, Gough Andrew, Kalden Joachim, Malaise Michel, Mola Emilio Martín, Pavelka Karel, Sany Jacques, Settas Lucas, Wajdula Joseph, Pedersen Ronald, Fatenejad Saeed, Sanda Marie, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, 10.1016/s0140-6736(04)15640-7
  11. Maini Ravinder N., Breedveld Ferdinand C., Kalden Joachim R., Smolen Josef S., Davis Diana, MacFarlane John D., Antoni Christian, Leeb Burkhard, Elliott Michael J., Woody James N., Schaible Thomas F., Feldmann Marc, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, 10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w
  12. Breedveld Ferdinand C., Weisman Michael H., Kavanaugh Arthur F., Cohen Stanley B., Pavelka Karel, Vollenhoven Ronald van, Sharp John, Perez John L., Spencer-Green George T., , The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment, 10.1002/art.21519
  13. Emery Paul, Fleischmann Roy M., Moreland Larry W., Hsia Elizabeth C., Strusberg Ingrid, Durez Patrick, Nash Peter, Amante Eric Jason B., Churchill Melvin, Park Won, Pons-Estel Bernardo Antonio, Doyle Mittie K., Visvanathan Sudha, Xu Weichun, Rahman Mahboob U., Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis, 10.1002/art.24638
  14. Emery Paul, Fleischmann Roy, van der Heijde Désirée, Keystone Edward C., Genovese Mark C., Conaghan Philip G., Hsia Elizabeth C., Xu Weichun, Baratelle Anna, Beutler Anna, Rahman Mahboob U., The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy, 10.1002/art.30263
  15. Arnett Frank C., Edworthy Steven M., Bloch Daniel A., Mcshane Dennis J., Fries James F., Cooper Norman S., Healey Louis A., Kaplan Stephen R., Liang Matthew H., Luthra Harvinder S., Medsger Thomas A., Mitchell Donald M., Neustadt David H., Pinals Robert S., Schaller Jane G., Sharp John T., Wilder Ronald L., Hunder Gene G., The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, 10.1002/art.1780310302
  16. Fries James F., Spitz Patricia, Kraines R. Guy, Holman Halsted R., Measurement of patient outcome in arthritis, 10.1002/art.1780230202
  17. Felson David T., Anderson Jennifer J., Boers Maarten, Bombardier Claire, Furst Daniel, Goldsmith Charles, Katz Linda M., Lightfoot Robert, Paulus Harold, Strand Vibeke, Tugwell Peter, Weinblatt Michael, James Williams H., Wolfe Frederick, Kieszak Stephanie, American college of rheumatology preliminary definition of improvement in rheumatoid arthritis, 10.1002/art.1780380602
  18. Heijde Désirée M. F. M. Van Der, Leeuwen Miek A. Van, Riel Piet L. C. M. Van, Koster Anja M., Hof Martin A. Van't, Rijswijk Martin H. Van, Putte Levinus B. A. Van De, Biannual Radiographic Assessments of Hands and Feet in a Three-Year Prospective Followup of Patients with Early Rheumatoid Arthritis, 10.1002/art.1780350105
  19. van Gestel A. M., Prevoo M. L. L., van't Hof M. A., van Rijswijk M. H., van de Putte L. B. A., van Riel P. L. C. M., Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, 10.1002/art.1780390105
  20. Wells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel P L C M, Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate, 10.1136/ard.2007.084459
  21. CASTREJON I., ORTIZ A. M., TOLEDANO E., CASTANEDA S., GARCIA-VADILLO A., PATINO E., GONZALEZ-ALVARO I., Estimated Cutoff Points for the 28-Joint Disease Activity Score Based on C-reactive Protein in a Longitudinal Register of Early Arthritis, 10.3899/jrheum.091333
  22. Smolen J. S., Breedveld F. C., Schiff M. H., Kalden J. R., Emery P., Eberl G., van Riel P. L., Tugwell P., A simplified disease activity index for rheumatoid arthritis for use in clinical practice, 10.1093/rheumatology/keg072
  23. Aletaha Daniel, Nell Valerie PK, Stamm Tanja, Uffmann Martin, Pflugbeil Stephan, Machold Klaus, Smolen Josef S, 10.1186/ar1740
  24. Aletaha Daniel, Smolen Josef S., The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care, 10.1016/j.berh.2007.02.004
  25. Kay Jonathan, Matteson Eric L., Dasgupta Bhaskar, Nash Peter, Durez Patrick, Hall Stephen, Hsia Elizabeth C., Han John, Wagner Carrie, Xu Zhenhua, Visvanathan Sudha, Rahman Mahboob U., Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study, 10.1002/art.23383
  26. Guyatt Gordon, Walter Stephen, Norman Geoff, Measuring change over time: Assessing the usefulness of evaluative instruments, 10.1016/0021-9681(87)90069-5
  27. Pye S. R., Adams J. E., Ward K. A., Bunn D. K., Symmons D. P. M., O'Neill T. W., Disease activity and severity in early inflammatory arthritis predict hand cortical bone loss, 10.1093/rheumatology/keq181
  28. Smolen Josef S., Van Der Heijde Désirée M. F. M., St.Clair E. William, Emery Paul, Bathon Joan M., Keystone Edward, Maini Ravinder N., Kalden Joachim R., Schiff Michael, Baker Daniel, Han Chenglong, Han John, Bala Mohan, , Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial, 10.1002/art.21678
  29. van der Heijde Désirée, Klareskog Lars, Rodriguez-Valverde Vicente, Codreanu Catalin, Bolosiu Horatiu, Melo-Gomes Jose, Tornero-Molina Jesus, Wajdula Joseph, Pedersen Ronald, Fatenejad Saeed, , Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial, 10.1002/art.21655
  30. Hsia Elizabeth C., Cush John J., Matteson Eric L., Beutler Anna, Doyle Mittie K., Hsu Benjamin, Xu Stephen, Rahman Mahboob U., Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials, 10.1002/acr.21788
  31. Hsia Elizabeth C., Schluger Neil, Cush John J., Chaisson Richard E., Matteson Eric L., Xu Stephen, Beutler Anna, Doyle Mittie K., Hsu Benjamin, Rahman Mahboob U., Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, 10.1002/art.34382